skip to content

Graduate Admissions

Course closed:

Metabolic and Cardiovascular Disease is no longer accepting new applications.

Ana Vujic (2008–12). Ana’s third rotation involved studies of differential methylation in end-stage cardiomyopathy in human hearts, which developed into a PhD project studying the epigenetic regulation of dilated cardiomyopathy. This involved generating conditional knockout mice and setting up surgical models of cardiac hypertrophy and dilatation, and a left-ventricular catheterization model to determine left ventricular function. Ana also used specialised imaging techniques including echocardiography, PET and MRI. These studies revealed a novel epigenetic mechanism regulating progression to dilated cardiomyopathy (J.Mol.Cell Cardiol. 2015;82:174-183, Circulation 2011;124:2411-22, Genome Med. 2010;2:37).

Ana was awarded an American Heart Association Young Investigator Travel Award in 2012 to present her work in Los Angeles. Ana also taught the specialised imaging techniques on the Murine Genetics and Cardiometabolic Phenotyping Course organised by the IMS with the European Atherosclerosis Society.

Following her PhD Ana spent one year as a postdoc at the National University of Singapore and is now a postdoc at Harvard Medical School where she is studying hormonal regulation of age-associated diastolic heart failure and cardiac regeneration. Ana’s goal is to return to the UK to develop her own team investigating
the potential of biomaterials to enhance regeneration in the cardiovascular system.

Ana Vijic (April 2016)

Paul Richards (2010–14) undertook rotation projects with Reimann/Gribble, Davenport/Maguire and Evans/Heisler, gaining experience in enteroendocrine physiology, cardiovascular pharmacology and the neurochemistry of feeding behaviour. During his PhD with Fiona Gribble, Paul characterised cell types involved in the enteroendocrine axis in mouse and human, demonstrating the overlapping profiles and fates of enteroendocrine cells (Endocrinology 2012;153:3054-65; Diabetologia 2013;56:1413-6, Dis. Model Mech. 2014;7:1275-86), localisation of a new gut hormone Insl5 to colonic L-cells (Proc. Natl. Acad. Sci. 2014;111:11133-8), impairment of L-cell function by high-fat diet (Peptides 2015), and identification of GLP1-receptor-expressing cell types representing the translational target targets of clinically used GLP-1 analogues (Diabetes 2014;63:1224-33). He additionally developed methodologies to purify and profile human L-cells in collaboration with Novartis (project ongoing).

Paul successfully applied for a three-year personal fellowship as part of the Revive Postdoc programme at the Pasteur Institute, Paris, to study G-protein coupled receptors on pancreatic islet cell types and their interaction with gut hormones. His goal is to develop this work to create an independent research programme.

Paul Roberts (April 2016)

Luke Burke (2010–14) undertook rotation projects with Heisler, Farooqi/Fletcher and Coll, gaining experience in neuroscience approaches in animals and behavioural studies in humans. Work from Luke's second rotation project is published in Int J Obes. 2014; 36:1245-7.

Luke's PhD combined in vivo pharmacology and transgenic technology to elucidate functional neuroanatomy in mice, providing training in behavioural analysis of feeding and histological studies. Luke also worked on the newly approved weight-loss drug lorcaserin, jointly supervised by Mark Evans, identifying a novel circuit through which it improves blood-sugar control. His PhD resulted in several publications (eg, Endocrinology 2014;155:3732-8, Behav Brain Res. 2014;266:201-6, Cell Metab. 2014;20:1030-7, Genes Brain Behav. 2012;11:291-302), and featured in national press.

Luke was selected to give an oral presentation at the Keystone Meeting ‘Neural Control of Metabolic Physiology and Disease’ (April 2015) and ACERO (April 2015), winning the Guarantors of Brain 2015 Travel Award. He also won the prize for the best poster at the 2012 Cambridge Neuroscience Conference.

Luke spent 18 months  as post-doc working with Clemence Blouet at the IMS before moving to Medimmune. 

Luke Burke (April 2016)

Key Information

1+3 years full-time

Doctor of Philosophy
Master of Research in the first instance

Department of Clinical Biochemistry


Course on Department Website

Dates and deadlines:

Applications open
Sept. 3, 2018
Application deadline
Dec. 13, 2018
Course Starts
Oct. 1, 2019

Some courses can close early. See the Deadlines page for guidance on when to apply.

Graduate Funding Competition
Dec. 5, 2018
Gates Cambridge US round only
Oct. 10, 2018

Similar Courses